HomeFilePharmacology

Pharmacology

View Category

HIGHLIGHTS

FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels

It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients;...
solaci -
Learn More
Antithrombotic Anticoagulants

COMPASS: A New Place for Rivaroxaban in Chronic Ischemic Heart Disease

Combining low doses of rivaroxaban and aspirin seems to be the best strategy for patients with stable...
solaci -
Learn More
HIGHLIGHTS

CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events

This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with...
solaci -
Learn More
Acute coronary syndromes

VALIDATE-SWEDEHEART: bivalirudin seems to be losing ground

Another important work that does not see the benefits of bivalirudin over heparin as monotherapy as regards both...
solaci -
Learn More
Antithrombotic Anticoagulants

RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI

RE-DUAL PCI outcomes have been published by the  New England Journal of Medicine along with their presentation at...
solaci -
Learn More
Antiplatelet

Dual antiplatelet therapy discontinuation causes more thrombotic events at 12 months

Several randomized studies have shown that dual antiplatelet therapy (DAPT) is as effective to prevent thrombotic events in...
solaci -
Learn More
Day 2

SOLACI 2017 | BRS: Present & Future

Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Stephen...
solaci -
Learn More
Day 2

SOLACI CACI 2017 | BRS: Presente y Futuro

Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Stephen...
solaci -
Learn More